Publication & Citation Trends
Most Cited Works
Publications
48 total
Abstract 5784: Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer
Cited by 0
Semantic Scholar
Discovery and characterization of FX-909, a covalent inverse agonist of PPARG rationally designed to impose a powerful repressive bias in PPARG for the treatment of PPARG/RXRA-activated muscle-invasive urothelial cancers
Cited by 0
Semantic Scholar
Novel inhibitors of the luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) durably eradicate tumors in urothelial cancer (UC) animal models OA
Cited by 0
Semantic Scholar
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion PDF
Cited by 93
OpenAlex
Cryo-EM structure of human ATP-citrate lyase in complex with a potent inhibitor OA
Cited by 0
Semantic Scholar
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations PDF
Cited by 451
OpenAlex
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency PDF
Cited by 125
OpenAlex
Research Topics
Cancer, Hypoxia, and Metabolism
(12)
Acute Myeloid Leukemia Research
(10)
Enzyme Structure and Function
(9)
Epigenetics and DNA Methylation
(6)
Endoplasmic Reticulum Stress and Disease
(6)
Frequent Co-Authors
Affiliations
Clark University
Howard Hughes Medical Institute
University of Alabama at Birmingham
Agios Pharmaceuticals (United States)
Q Therapeutics (United States)